Alimta

(Pemetrexed disodium)

Phase 3Small molecule

Pemetrexed is used to treat certain types of cancer, including lung cancer and mesothelioma (a cancer caused by asbestos exposure). It works by slowing or stopping the growth of cancer cells in the body.[1] Alimta is currently being investigated across 41 indications[3], with its most advanced program in Phase 3.[1]

Alimta is one of 458 small molecule programs targeting Lung Non-Small Cell Carcinoma. It is currently in Phase 3.

Indications

219

Total Trials

117

Active Trials

457

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Lung Non-Small Cell CarcinomaCompleted

Double BlindRecruiting

Carcinoma, Non-Small-Cell LungActive, not recruiting

Metastatic Non Small Cell Lung CancerActive, not recruiting

Advanced MalignanciesActive, not recruiting

Malignant NeoplasmRecruiting

Locally Advanced Lung Non-Small Cell CarcinomaRecruiting

Peritoneal Malignant MesotheliomaRecruiting

Lung Neoplasm MalignantRecruiting

Biphasic MesotheliomaTerminated

Lung Non-Small Cell CarcinomaPhase 3

Completed

Double BlindPreclinical

Recruiting

Carcinoma, Non-Small-Cell LungPhase 3

Active, not recruiting

Metastatic Non Small Cell Lung CancerPhase 3

Active, not recruiting

Advanced MalignanciesPhase 3

Active, not recruiting

Malignant NeoplasmPhase 2

Recruiting

Locally Advanced Lung Non-Small Cell CarcinomaPhase 3

Recruiting

Peritoneal Malignant MesotheliomaPhase 2

Recruiting

Lung Neoplasm MalignantPhase 2

Recruiting

Biphasic MesotheliomaPhase 3

Terminated

Showing 10 of 41 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

32 2

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

75 3

Pyrotinib

HHengrui Therapeutics, Inc.

Phase 3

3 4

TGRX-326

SShenzhen TargetRx Co., Ltd.

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—9

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 10

Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT03775486

PreclinicalActive, not recruiting

Lung Non-Small Cell Carcinoma

NCT02194738

Q4 2026

PreclinicalActive, not recruiting

Advanced Malignant Solid Neoplasm

NCT02535312

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT03425643

Phase 2Active, not recruiting

Malignant Pleural Mesothelioma

NCT06318286

Phase 3Active, not recruiting

Non-Small-Cell Lung

NCT05261399

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer74 trials

Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00280748·10 enrolled

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

Withdrawn·UUniversity of California, San Francisco·Phase 2·NCT04061590

Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·MMayo Clinic·Phase 2·NCT00407550·19 enrolled

Show 71 more trials

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Withdrawn·EECOG-ACRIN Cancer Research Group·Phase 2·NCT02607423

PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Completed·—·Phase 1·NCT01723800·9 enrolled

Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00389688·13 enrolled

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Recruiting·SShanghai Chest Hospital·Phase 2·NCT06659042·32 enrolled

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01928160

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Unknown status·IIstituto Scientifico H. San Raffaele·Phase 3·NCT00989690·275 enrolled

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·—·Phase 2·NCT00660816·46 enrolled

Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00863512·34 enrolled

Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer

Terminated·BBarbara Ann Karmanos Cancer Institute·N/A·NCT02145078·4 enrolled

Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3

Completed·WWake Forest University Health Sciences·Phase 2·NCT02426658·16 enrolled

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02535325·17 enrolled

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00698815·130 enrolled

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting· BeiGene logo

BeiGene·Phase 3·NCT04379635·453 enrolled

Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Completed·UUniversity of Washington·Phase 2·NCT00227539·25 enrolled

Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00248495·38 enrolled

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00410904·60 enrolled

Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00301808·29 enrolled

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00738881·23 enrolled

Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01344824·38 enrolled

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Active, not recruiting·NNRG Oncology·Phase 2·NCT03137771·218 enrolled

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT01041781·313 enrolled

Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Completed·UUniversity of California, Davis·Phase 1/2·NCT00387322·42 enrolled

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

Terminated·SSWOG Cancer Research Network·Phase 2·NCT02134912·1 enrolled

Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00520845·23 enrolled

Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00022646·157 enrolled

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

Completed·—·Phase 2·NCT00950365·79 enrolled

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00454194·110 enrolled

Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT01958372·11 enrolled

Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT01664754·8 enrolled

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00798603·65 enrolled

Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00268489·48 enrolled

Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Completed·UUniversity of California, Davis·Phase 1/2·NCT00389805·27 enrolled

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT03366766·14 enrolled

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00438204·39 enrolled

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Completed·SSWOG Cancer Research Network·Phase 2·NCT03971474·166 enrolled

Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00117962·109 enrolled

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01935947·17 enrolled

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT01784640·13 enrolled

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06312137·780 enrolled

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT06899126·686 enrolled

A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT06236438·840 enrolled

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06561386·1,000 enrolled

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07190248·675 enrolled

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT06772623·252 enrolled

A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04351555·358 enrolled

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Recruiting· Roche logo

Roche·Preclinical·NCT05789082·320 enrolled

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting· Roche logo

Roche·Phase 3·NCT06793215·600 enrolled

A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT06712316·1,580 enrolled

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Active, not recruiting· Roche logo

Roche·Preclinical·NCT03178552·1,000 enrolled

A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04035486·587 enrolled

A Phase 1/2, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Recruiting·DDizal Pharmaceuticals·Preclinical·NCT07070440·180 enrolled

Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Active, not recruiting· Arcus Biosciences logo

Arcus Biosciences·Phase 2·NCT04736173·169 enrolled

A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06448754·194 enrolled

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02609776·751 enrolled

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07100080·500 enrolled

A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT07680790·850 enrolled

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05061550·630 enrolled

A Prospective, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With Tislelizumab and Platinum-based Doublet Chemotherapy as Induction/Conversion Therapy for Potentially Resectable Stage III Non-small Cell Lung Cancer With Bulky Disease.

Not yet recruiting·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT07775040·43 enrolled

A Phase I-II, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status

Completed· Roche logo

Roche·Phase 3·NCT06624059·11 enrolled

A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06564844·25 enrolled

KEYMAKER-U01 Substudy 01G: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab With or Without Platinum-based Chemotherapy in Treatment-Naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06731907·90 enrolled

Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT04253964·105 enrolled

A Phase II/III Randomized Controlled Clinical Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Preclinical·NCT07642024·90 enrolled

Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06745882·318 enrolled

A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

Active, not recruiting· Roche logo

Roche·Phase 3·NCT02486718·1,280 enrolled

A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT03425643·797 enrolled

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT06475300·570 enrolled

A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT05775289·182 enrolled

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels

Active, not recruiting· Regeneron logo

Regeneron·Preclinical·NCT05800015·160 enrolled

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03519971·328 enrolled

A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06711900·432 enrolled

Carcinoma, Non-Small-Cell Lung11 trials

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06623422·680 enrolled

A Randomized, Open-label, Controlled, Multicenter Phase 3 Trial of HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation.

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 3·NCT07822542·448 enrolled

SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06119581·1,264 enrolled

Show 8 more trials

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Recruiting·MMirati Therapeutics Inc.·Phase 3·NCT06875310·630 enrolled

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04538664·308 enrolled

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05498428·520 enrolled

A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT07586202·68 enrolled

Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT05298423·610 enrolled

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT04165070·450 enrolled

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04988295·776 enrolled

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03456076·257 enrolled

Solid Tumor10 trials

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07492680·260 enrolled

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT05067283·830 enrolled

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors

Recruiting·CCStone Pharmaceuticals·Preclinical·NCT06741644·800 enrolled

Show 7 more trials

A Phase 1 Study to Evaluate the Safety and Tolerability of GS-5319 Monotherapy and Combination Therapy in Adults With MTAP-deleted Advanced Solid Tumors

Recruiting· Gilead logo

Gilead·Phase 1·NCT07128303·476 enrolled

Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)

Recruiting·MMirati Therapeutics Inc.·Phase 2·NCT07415031·170 enrolled

A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab and/or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Terminated· Astellas logo

Astellas·Phase 1·NCT05083481·226 enrolled

A Phase 1b/2, Multicenter, 2-part, Open-label Trial to Evaluate DS-3939a in Participants With Solid Tumors

Not yet recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Preclinical·NCT07739966·400 enrolled

A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

Recruiting· Astellas logo

Astellas·Phase 1·NCT05382559·681 enrolled

A Phase 1 Study of ASP1002 in Participants With Metastatic or Locally Advanced Solid Tumors

Recruiting· Astellas logo

Astellas·Phase 1·NCT05719558·798 enrolled

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

Recruiting·SSynthekine·Preclinical·NCT05098132·364 enrolled

Malignant Pleural Mesothelioma6 trials

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01085630·72 enrolled

Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00227630·59 enrolled

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00101283·32 enrolled

Show 3 more trials

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01105390

First-line Pembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Malignant Pleural Mesothelioma：Multi-Institutional, Single-Arm Phase 2 Trial

Active, not recruiting·HHyogo Medical University·Phase 2·NCT06318286·25 enrolled

Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable Malignant Pleural Mesothelioma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04162015·22 enrolled

Metastatic Non Small Cell Lung Cancer6 trials

A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07063745·590 enrolled

A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04410796·571 enrolled

A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT05226598·739 enrolled

Show 3 more trials

A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05722015·377 enrolled

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06212752·39 enrolled

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05984277·895 enrolled

72 more indications

Non-small Cell Lung Cancer (NSCLC)5 trials

Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Suspended·NNational Cancer Institute (NCI)·Preclinical·NCT06694454·60 enrolled

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07680764·160 enrolled

A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03775486·401 enrolled

Show 2 more trials

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06305754·550 enrolled

A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06074588·556 enrolled

Non-Squamous Non-Small Cell Lung Cancer5 trials

Randomized, Multicenter, Multinational, Double-Blind Study to Compare the Pharmacokinetics, Efficacy, Safety and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) Versus Keytruda® in Combination With Chemotherapy for the Treatment of Patients With Advanced Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (BENITO Study)

Active, not recruiting·MmAbxience Research S.L.·Phase 3·NCT06687369·726 enrolled

A Randomized, Open-label, Multicenter Phase II/III Clinical Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Preclinical·NCT07739186·120 enrolled

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06627647·1,160 enrolled

Show 2 more trials

A Phase II Study of Lenvatinib (E7080/MK-7902) in Combination With Carboplatin Pemetrexed and Pembrolizumab (MK-3475) for Patients With Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Harboring EGFR Mutations

Completed·JJuntendo University·Phase 2·NCT05258279·30 enrolled

A Phase II Study Evaluating the Efficacy and Safety of IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT07122687·170 enrolled

Metastatic Solid Tumors3 trials

Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors

Completed·SSan Antonio Cancer Institute·Phase 1·NCT00003711

Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00320073·41 enrolled

Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00573690·31 enrolled

Patients With Advanced Solid Tumors3 trials

Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors

Completed·MMayo Clinic·Phase 1·NCT00390000·29 enrolled

Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors

Completed·VVirginia Commonwealth University·Phase 1·NCT01450384·37 enrolled

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00703638·16 enrolled

Lung Non-Small Cell Carcinoma3 trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04267848·1,210 enrolled

Perioperative Versus Adjuvant Systemic Therapy in Patients With Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT06632327·37 enrolled

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02194738·8,300 enrolled

Metastatic Urothelial Cancer2 trials

Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02693717·7 enrolled

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Recruiting·SShanghai Miracogen Inc.·Phase 3·NCT05754853·290 enrolled

Malignant Mesothelioma2 trials

Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00005636

Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma

Completed·CCentre Oscar Lambret·Phase 2·NCT00541073·60 enrolled

Cervical Cancer2 trials

Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00691301·55 enrolled

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06459180·686 enrolled

Lung Cancer, Non-squamous, Non-small Cell2 trials

Beamion 44: A Randomized, Open-label, Multi-center Phase IIa Platform Trial to Evaluate the Safety and Tolerability of Zongertinib Plus Platinum-based Doublet Chemotherapy With or Without Pembrolizumab (and Potential Other Combinations) in Treatment-naïve Patients With Locally Advanced/Metastatic Non-squamous NSCLC With Activating HER2 Mutations

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT07486817·60 enrolled

Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT06151574·428 enrolled

Non Small Cell Lung Cancer Metastatic2 trials

Phase II Trial Assessing 1st Line and 2nd Line Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Not yet recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT07420439·108 enrolled

A Randomized, Phase II Study of Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed and Carboplatin (PC) for Metastatic Non-Squamous NSCLC

Terminated·UUniversity of Utah·Phase 2·NCT04163432·43 enrolled

Biphasic Mesothelioma2 trials

A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03228537·28 enrolled

Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)

Terminated·NNRG Oncology·Phase 3·NCT04158141·16 enrolled

Recurrent Cancer1 trial

Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix

Completed·GGynecologic Oncology Group·Phase 2·NCT00087113

Salivary Gland Cancer1 trial

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Active, not recruiting·MMayo Clinic·Phase 2·NCT04895735·45 enrolled

Solid Tumors1 trial

Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors

Completed·CChildren's Oncology Group·Phase 1·NCT00070473·33 enrolled

Breast Cancer1 trial

LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006007·59 enrolled

Chondrosarcoma1 trial

S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00107419·75 enrolled

Small Cell Lung Cancer1 trial

Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00227565·50 enrolled

Gastric Cancer1 trial

Phase II Study of Pemetrexed in Advanced or Recurrent Gastric Cancer After Chemotherapy

Completed·SSun Yat-sen University·Phase 2·NCT01953419·34 enrolled

Advanced Cancer1 trial

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00053209·46 enrolled

Ovarian Cancer1 trial

Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

Completed·UUniversity of Arizona·Phase 1·NCT00702299·15 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00003706·50 enrolled

Fallopian Tube Cancer1 trial

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed·—·Phase 2·NCT01001910·22 enrolled

Gallbladder Cancer1 trial

Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00059865·68 enrolled

Pregnancy1 trial

Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy

Terminated·GGynecologic Oncology Group·Phase 2·NCT00096187·55 enrolled

Locally Advanced Head and Neck Cancer1 trial

Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00503997·42 enrolled

Primary Peritoneal Cancer1 trial

Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00087087·51 enrolled

Intensity-modulated Radiation Therapy1 trial

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Terminated·WWake Forest University Health Sciences·Phase 1/2·NCT00573989·27 enrolled

Endometrial Cancer1 trial

Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00087100·51 enrolled

Lymphoma1 trial

Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00470405·25 enrolled

Lung Cancer1 trial

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Active, not recruiting· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT01993810·330 enrolled

Pancreatic Cancer1 trial

Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Terminated·WWake Forest University Health Sciences·Phase 1·NCT00310050·4 enrolled

Prostate Cancer1 trial

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Completed·UUniversity of Southern California·Phase 2·NCT01338792·47 enrolled

KRAS P.G12C1 trial

A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Recruiting·DD3 Bio (Wuxi) Co., Ltd·Preclinical·NCT05410145·442 enrolled

HER2 Mutation1 trial

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Recruiting· Bayer logo

Bayer·Phase 3·NCT06452277·444 enrolled

Epithelioid Mesothelioma1 trial

A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT01064648·117 enrolled

Recurrent Lung Non-Small Cell Carcinoma1 trial

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04092283·660 enrolled

Ewing sarcoma1 trial

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting·IInhibrx Biosciences, Inc·Phase 1·NCT03715933·411 enrolled

Metastatic Solid Tumor1 trial

An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4/BRG1 Alterations

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06561685·340 enrolled

Advanced Lung Non-Small Cell Carcinoma1 trial

A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT06096844·304 enrolled

Lung Adenocarcinoma1 trial

A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05198830·42 enrolled

Stage III Lung Cancer AJCC v81 trial

Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04892953·51 enrolled

Malignant Neoplasm1 trial

KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07252739·140 enrolled

Lung Neoplasm Malignant1 trial

KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06788912·60 enrolled

Recurrent or Metastatic Cervical Cancer1 trial

A Randomized, Controlled, Open-Label, Multi-center, Phase III Study of JSKN033 Versus Investigator's Choice of Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Platinum-Based Chemotherapy and PD-1/L1 Inhibitor Therapy

Not yet recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 3·NCT07797153·368 enrolled

Malignant Neoplam1 trial

A Phase 2, Open-label Clinical Study to Evaluate the Safety and Efficacy of MK-2010 as Monotherapy and in Combination

Not yet recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07793942·480 enrolled

Lung Non-Squamous Non-Small Cell Carcinoma1 trial

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03793179·600 enrolled

Metastatic Biliary Tract Carcinoma1 trial

A Phase Ib/II Basket Study of BMS-986504 in Combination With Pemetrexed for Metastatic Solid Tumors With MTAP Deletion

Recruiting·NNorthwestern University·Preclinical·NCT07594626·72 enrolled

Selected Advanced Solid Tumors1 trial

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT03530397·400 enrolled

Large B-cell Lymphoma1 trial

Phase I Pilot Trial of Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas

Not yet recruiting·AAllison Winter·Phase 1·NCT07608731·18 enrolled

Locally Advanced Lung Non-Small Cell Carcinoma1 trial

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer

Recruiting·NNRG Oncology·Phase 3·NCT05624996·474 enrolled

Urothelial Carcinoma1 trial

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05335941·10 enrolled

Peritoneal Malignant Mesothelioma1 trial

Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05001880·66 enrolled

Advanced Non-squamous Non-small-cell Lung Cancer1 trial

An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Recruiting·AAllist Pharmaceuticals, Inc.·Phase 3·NCT06416410·392 enrolled

Metastatic Lung Non-Small Cell Carcinoma1 trial

A Phase 1b Study of Ensartinib in Combination With Platinum-Based Chemotherapy and Bevacizumab in ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04837716·12 enrolled

Mesothelioma1 trial

Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00715611·65 enrolled

Resectable Non-small Cell Lung Cancer1 trial

A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT06161441·195 enrolled

Non Small Cell Lung Carcinoma NSCLC1 trial

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT02542293·953 enrolled

Non-Small-Cell Lung1 trial

A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05261399·341 enrolled

Non-Small Cell Lung Carcinoma1 trial

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT02453282·1,118 enrolled

Malignant Solid Tumor1 trial

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

Active, not recruiting· Genmab logo

Genmab·Preclinical·NCT04083599·350 enrolled

Advanced Malignant Solid Neoplasm1 trial

Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02535312·30 enrolled

Non-squamous NSCLC1 trial

A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance

Completed·EETOP IBCSG Partners Foundation·Phase 2·NCT04245085·95 enrolled

Pleural Mesothelioma1 trial

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06097728·863 enrolled

Mesothelioma Malignant Advanced1 trial

A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma

Completed·EETOP IBCSG Partners Foundation·Phase 3·NCT03762018·400 enrolled

Malignant Peritoneal Mesothelioma1 trial

ICARuS II (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multicenter, Randomized Phase II Trial of Normothermic Intraperitoneal Chemotherapy and Intravenous Chemotherapy After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06057935·64 enrolled

Advanced or Metastatic Non-small Cell Lung Cancer1 trial

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06996782·152 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06607185·750 enrolled

Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant1 trial

A Phase II Trial to Evaluate Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient Advanced Urothelial Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03744793·18 enrolled

Lung Cancer (NSCLC)1 trial

A Phase II Study of Ivonescimab as Monotherapy or in Combination With Platinum/Pemetrexed Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring Actionable Genomic Alterations (AGAs)

Recruiting·MMassachusetts General Hospital·Phase 2·NCT07405190·46 enrolled

Locally Advanced or Metastatic Non-small Cell Lung Cancer1 trial

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05048797·454 enrolled

Solid Tumor, Adult1 trial

First-in-Human Dose Study of IOA-244 in Patients With Advanced or Metastatic Cancers

Active, not recruiting·IiOnctura·Phase 1·NCT04328844·210 enrolled

Unspecified2 trials

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03899155·1,500 enrolled

An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03768063·1,000 enrolled

Regulatory

FDA Approval Timeline[4]

Sep 7, 2007

ALIMTA

NDA NDA021462

Feb 8, 2020

PEMFEXY

NDA NDA209472

Aug 21, 2020

PEMETREXED

NDA NDA208419

May 26, 2022

PEMETREXED DISODIUM

NDA NDA214657

Jun 22, 2022

PEMETREXED DISODIUM

NDA NDA214218

Jul 19, 2022

PEMETREXED DISODIUM

NDA NDA214408

May 22, 2023

PEMETREXED

NDA NDA215179

Sources

References

[1]
ClinicalTrials.gov — 219 trial records for Pemetrexed disodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pemetrexed disodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pemetrexed disodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA215179). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Eagle Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: GAR Transformylase Inhibitor; Dihydrofolate Reductase Inhibitor; Thymidylate Synthase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEagle Pharmaceuticals, Inc.